Novartis Completes Divestiture of Influenza Vaccines Business to CSL Limited for $275M
August 02, 2015 at 19:55 PM EDT
CSL Limited acquired influenza vaccines business of Novartis (NYSE: NVS), including influenza vaccines development pipeline Basel, ...